reviewClinical Infectious DiseasesMar 1, 2003Closed access

Voriconazole: A New Triazole Antifungal Agent

Wayne State University · Office of Infectious Diseases

PubMed
Indexed incrossrefpubmed

Abstract

Voriconazole is a second-generation azole antifungal agent that shows excellent in vitro activity against a wide variety of yeasts and molds. It can be given by either the intravenous or the oral route; the oral formulation has excellent bioavailability. The side effect profile of voriconazole is unique in that non-sight-threatening, transient visual disturbances occur in approximately 30% of patients given the drug. Rash (which can manifest as photosensitivity) and hepatitis also occur. The potential for drug-drug interactions is high and requires that careful attention be given to dosage regimens and monitoring of serum levels and effects of interacting drugs. Voriconazole has been approved for the treatment…

Citation impact

775
total citations
FWCI
23.44
Percentile
100%
References
46
Citations per year

Authors

2

Topics & keywords

Keywords
  • Voriconazole
  • Medicine
  • Aspergillosis
  • Drug
  • Azole
  • Rash
  • Pharmacology
  • Triazole
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.